Johnson Controls International plc (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, announced ...

Johnson & Johnson JNJ reported 2.4% sales growth (2.3% in innovative medicine, 2.5% in medtech) and 2.2% adjusted EPS growth in the first quarter. Management raised reported sales growth guidance ...

Marcella joins from Johnson & Johnson Innovation and is an accomplished leader with extensive experience in immuno-oncology, precision medicine, and advanced therapy medicinal products (ATMPs).

Marcella joins from Johnson & Johnson Innovation and is an accomplished leader with extensive experience in immuno-oncology, precision medicine, and advanced therapy medicinal products (ATMPs).

Why it matters: Investors were concerned about how severely the headwinds from Stelara biosimilars and the Medicare Part D redesign would hit Johnson & Johnson's financials, as well as the ...

Patrick Verheyen Patrick Verheyen, Head, Johnson & Johnson Innovation, London speaks with pharmaphorum's Paul Tunnah about his work at the Innovation Centre in London. PT: What is the objective ...

Berman has 25 years of experience in general management and marketing, demonstrating a strong record of driving growth across ...

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...